METOCLOPRAMIDE HYDROCHLORIDE (metoclopramide hydrochloride) by Pfizer is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Approved for vomiting associated with emetogenic cancer chemotherapy, postoperative nausea, vomiting in those circumstances where nasogastric suction is undesirable. First approved in 1989.
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on METOCLOPRAMIDE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pfizer is hiring 10 roles related to this product